ISIntuitive Surgical company profile
$443.59+0.84%Close 13 Nov 2026 · Market value $152.6B
About Intuitive Surgical
Intuitive Surgical provides a comprehensive ecosystem for minimally invasive care, combining robotic-assisted systems, instruments and accessories, customer learning, and customer support services, all connected by a digital portfolio. Its main platforms are the da Vinci surgical systems, used across a range of surgical procedures, and the Ion endoluminal system, used for minimally invasive lung biopsies. The company's products are used by surgeons, physicians, hospitals, and healthcare systems, and it offers training pathways, simulation, field service, and digital analytics to these customers. Its da Vinci and Ion products are used by customers globally, supported by a network of field service engineers across the U.S., Canada, Europe, and Asia and by distributors around the world.
A summary of the business section of the company's latest annual report, filed 3 Feb 2026.
Company facts
| Ticker | ISRG · Nasdaq |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1035267 |
|---|
| Latest annual report | 10-K, filed 3 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Gary S. Guthart, Ph.D. | Director | 1.5M · < 1% | Sale under a 10b5-1 plan, 4 Nov 2026 |
|---|
| David J. Rosa | Chief Executive Officer (CEO) · Director | 439K · < 1% | Shares withheld for tax, 10 Jul 2026 |
|---|
| Mark P. Brosius | EVP & Chief Mfg and Supply Cha | 75.5K · < 1% | Sale under a 10b5-1 plan, 30 Oct 2026 |
|---|
| Craig H. Barratt, Ph.D. | Director | 47.9K · < 1% | Option exercise, 4 Nov 2026 |
|---|
| Henry L. Charlton | EVP & Chief Commercial and Mkt | 37.6K · < 1% | Shares withheld for tax, 28 Feb 2026 |
|---|
| Jamie E. Samath | EVP & CFO & Enterprise Technol | 26.3K · < 1% | Option exercise, 28 Feb 2026 |
|---|
| Amal M. Johnson | Director | 25.5K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Jami Dover Nachtsheim | Director | 21.1K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Gary H. Loeb | EVP & Chief Legal and Complian | 18.0K · < 1% | Sale under a 10b5-1 plan, 10 Nov 2026 |
|---|
| Joseph C. Beery | Director | 10.2K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Keith R. Leonard Jr. | Director | 10.2K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Monica P. Reed, M.D. | Director | 7.2K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Sreelakshmi Kolli | Director | 1.7K · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Lewis Chew | Director | 783 · < 1% | Option exercise, 30 Apr 2026 |
|---|
| Amy L. Ladd, M.D. | Director | 739 · < 1% | Sale under a 10b5-1 plan, 11 Aug 2026 |
|---|
| Widman Fredrik | VP Corporate Controller | — | Option exercise, 30 Oct 2026 |
|---|
| WADORS PATRICIA L | SVP Chief Human Resources Offi | — | Sale under a 10b5-1 plan, 23 Oct 2026 |
|---|
| Jeddi Iman | SVP & GM da Vinci Platforms & | — | Sale under a 10b5-1 plan, 1 Jun 2026 |
|---|
| Curet Myriam | EVP & Chief Medical Officer | — | Sale under a 10b5-1 plan, 10 Mar 2026 |
|---|
| Miller Brian Edward | EVP & Chief Digital Officer | — | Option exercise, 10 Nov 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ISRG in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.